The Market Reports

Synopsis
The global market for Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine was estimated to be worth US$ 410 million in 2024 and is forecast to a readjusted size of US$ 521 million by 2031 with a CAGR of 3.3% during the forecast period 2025-2031.
This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
Porcine Reproductive and Respiratory Syndrome (PRRS) vaccine is a biological product designed to prevent and control PRRS, a highly contagious viral disease that affects pigs. The vaccine works by stimulating the pig's immune system to produce a protective response against the PRRS virus, thereby reducing reproductive failures such as abortions and stillbirths in sows, as well as respiratory illness and mortality in piglets and growing pigs. PRRS vaccines are typically classified into modified live vaccines (MLVs) and inactivated vaccines, and they play a critical role in improving herd health and productivity in the swine industry worldwide.
The global PRRS vaccine market is primarily driven by the widespread prevalence and economic impact of Porcine Reproductive and Respiratory Syndrome in the swine industry. PRRS is one of the most devastating diseases affecting pigs, causing significant reproductive losses in breeding herds and severe respiratory distress in growing pigs. The virus's ability to mutate and persist in herds has made it difficult to eradicate, leading to chronic infections and substantial financial losses for pig farmers. As a result, governments and veterinary authorities in major pork-producing countries such as China, the United States, and countries in the European Union have emphasized vaccination as a critical component of disease control programs. Additionally, rising global pork consumption is pressuring producers to maintain healthier herds and ensure consistent productivity, further boosting demand for effective PRRS vaccines. Technological advancements in vaccine formulation—such as the development of region-specific or genotype-specific modified live vaccines (MLVs)—have improved vaccine efficacy, making immunization a more reliable and widely accepted preventive measure. Moreover, increasing biosecurity awareness and the integration of vaccination into herd health management systems are reinforcing the growth of the PRRS vaccine market globally.
Despite its importance, the PRRS vaccine market faces several challenges that limit its effectiveness and adoption in certain regions. One of the primary issues is the virus's high genetic variability, which complicates the development of universally effective vaccines. The presence of multiple genotypes and frequent mutations means that vaccine strains may not provide cross-protection against all circulating variants, leading to inconsistent results and partial immunity in vaccinated herds. Additionally, modified live vaccines (MLVs), while generally more effective than inactivated ones, carry risks of reversion to virulence or recombination with field strains, which raises safety concerns among producers and regulatory bodies. In developing regions, limited access to veterinary services, cold chain logistics, and affordability issues further hinder the widespread adoption of PRRS vaccination programs. Moreover, there remains a lack of standardized vaccination protocols across countries, and vaccine performance can vary depending on farm conditions, pig genetics, and co-infections with other pathogens. These factors make disease management complex and can reduce confidence in vaccination strategies. Overcoming these challenges requires continued investment in research and development of next-generation vaccines, improved diagnostic tools for strain identification, and stronger government support for vaccination campaigns and swine health education.
This report aims to provide a comprehensive presentation of the global market for Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine by region & country, by Type, and by Application.
The Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine.
Market Segmentation
By Company
China Animal Husbandry Co., Ltd.
Boehringer Ingelheim
MSD Animal Health
Sinopharm Animal Health
Ceva
Ruipu Biological
Qilu Animal Health
Dahuanong
CAVAC
Komipharm
Agrovet
Bioveta
Jinyu
Phibro Animal Health
Tiankang
Zoetis
Yongshun Biological
Pulike Biological
Segment by Type
Live vaccines
Inactivated vaccines
Segment by Application
Government bidding
Market sales
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index